Skip to main content
. 2021 Nov 16;13(11):1942. doi: 10.3390/pharmaceutics13111942

Table 2.

Genetic variants identified in GWAS that achieved a significance of at least 5 × 10−5 in the logistic regression analysis.

CHR SNV Gene Allele AF Analysis 1 Discovery p-Value Cohort OR
[95% CI]
Replication
p-Value
Cohort OR
[95% CI]
1 rs11185202 74 kb from AMY1C, 136 kb from AMY1B T 0.41 Case-Control 2.13 × 10−5 0.36 [0.23–0.58] 0.88 0.96 [0.57–1.61]
1 rs66539320 lncRNA G 0.18 Case-Control 3.72 × 10−5 0.33 [0.19–0.56] 0.56 1.24 [0.60–2.54]
1 rs382092 lncRNA T 0.36 Extreme Phenotypes 2.32 × 10−5 4.03 [2.11–7.68] 0.31 0.57 [0.19–1.68]
2 rs17687727 lncRNA A 0.16 Extreme Phenotypes 4.73 × 10−5 4.92 [2.29–10.66] 0.80 1.17 [0.34–4.07]
4 rs2270271 GPR78 T 0.46 Case-Control 1.51 × 10−5 0.38 [0.25–0.59] 0.84 0.95 [0.58–.’54]
9 rs377186 RCL1 A 0.44 Case-Control 1.50 × 10−5 0.35 [0.22–0.57] 0.38 0.81 [0.50–1.30]
13 rs8000668 98 kb from ARHGEF7, and 101 kb from ANKRD10 T 0.52 Case-Control 2.50 × 10−5 0.40 [0.26–0.62] 0.41 0.79 [0.46–1.38]
19 rs62134260 4 kb from POLRMT, and 2 kb from FGF22 G 0.16 Case-Control 2.37 × 10−5 4.13 [2.14–7.97] 0.48 1.27 [0.65–2.47]
Extreme Phenotypes 2.23 × 10−5 5.76 [2.56–12.93] 0.021 8.2 [1.36–49.35]
20 rs6099854 225 kb from PMEPA1, and 214 kb from C20orf85 A 0.14 Extreme Phenotypes 3.77 × 10−5 6.57 [2.69–16.09] 0.42 0.42 [0.05–3.47]

1 Case-Control (Controls against Mild and Severe Cases, Discovery Cohort N = 226, Replication Cohort N = 123), Extreme Phenotypes (Controls against Severe Cases, Discovery Cohort N = 135, Replication Cohort N = 77). Abbreviations: AF, Allele Frequency in European Population; OR, Odds Ratio; CI, Confidence Interval; N, Sample Size; Kb, Kilobases; CHR, Chromosome; SNV, Single-nucleotide variant. Cumulative dose is used as covariate in each analysis. Significant p-values in the replication cohort (p-value < 0.05) are highlighted in bold.